Novo Nordisk Net Long-Term Debt 2010-2025 | NVO

Novo Nordisk net long-term debt from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
Novo Nordisk Annual Net Long-Term Debt
(Millions of US $)
2024 $10,593
2023 $-213
2022 $-341
2021 $2,461
2020 $725
2019 $-111
2018 $14
2017 $N/A
2016 $N/A
2015 $N/A
2014 $N/A
2013 $N/A
2012 $-87
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $42.122B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $769.590B 59.01
Johnson & Johnson (JNJ) United States $376.935B 15.59
AbbVie (ABBV) United States $339.891B 18.74
Roche Holding AG (RHHBY) Switzerland $267.554B 0.00
Novartis AG (NVS) Switzerland $255.117B 14.57
Merck (MRK) United States $205.453B 10.50
Pfizer (PFE) United States $141.224B 7.74
Sanofi (SNY) France $124.659B 12.28
Bayer (BAYRY) Germany $31.555B 6.42
Innoviva (INVA) United States $1.343B 14.08